Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

NCT02232061 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Fingolimod

Sponsor

Novartis Pharmaceuticals